Corbus Pharmaceuticals Holdings, INC. 8-K Filing

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
• $13.00 — on Stock"), at a price to the public of $13.00 per share and (ii) pre-funded warrants
• $12.9999 — mon Stock at a public offering price of $12.9999 per share, which represents the per sha
• $70.5 m — ption) are expected to be approximately $70.5 million, after deducting underwriting dis

Filing Documents

• crbp-20251030.htm (8-K) — 63KB
• crbp-ex1_1.htm (EX-1.1) — 432KB
• crbp-ex4_1.htm (EX-4.1) — 216KB
• crbp-ex5_1.htm (EX-5.1) — 22KB
• crbp-ex99_1.htm (EX-99.1) — 14KB
• crbp-ex99_2.htm (EX-99.2) — 13KB
• 0001193125-25-261722.txt ( ) — 982KB
• crbp-20251030.xsd (EX-101.SCH) — 31KB
• crbp-20251030_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 30, 2025, Corbus Pharmaceuticals Holdings, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC (the "Representative"), as representative of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of an aggregate of (i) 4,744,231 shares (the "Base Shares") of the Company's common stock, par value $0.0001 (the "Common Stock"), at a price to the public of $13.00 per share and (ii) pre-funded warrants to purchase up to 1,025,000 shares of Common Stock at a public offering price of $12.9999 per share, which represents the per share public offering price for the Base Shares less the $0.0001 per share exercise price for each Pre-Funded Warrant (the "Pre-Funded Warrants"). The Underwriters were also granted a 30-day option to purchase up to an additional 865,384 shares of Common Stock (the "Option Shares" and together with the Base Shares, the "Shares") at the public offering price. The Pre-Funded Warrants will be exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing prior notice to the Company, provided that any increase will not be effective until the 61st day after such notice is delivered to the Company. The net proceeds to the Company from the Offering (before giving effect to any exercise of the Underwriters' option) are expected to be approximately $70.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Offering is expected to close

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 30, 2025, the Company issued a press release regarding the launch of the Offering. On October 31, 2025, the Company issued a press release announcing that it had priced the Offering. Copies of the press releases are furnished hereto as Exhibits 99.1 and 99.2, respectively, to this Current Report and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated October 30, 2025 4.1 Form of Pre-funded Warrant 5.1 Opinion of Lowenstein Sandler LLP 23.1 Consent of Lowenstein Sandler LLP (contained in Exhibit 5.1) 99.1 Press Release dated October 30, 2025 99.2 Press Release dated October 31, 2025

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: November 3, 2025 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR